Company intelligence / Profile preview
Shanghai Junshi Biosciences Co., Ltd.
- Ownership
- Public · 1877.HK
- Employees
- ~2500
- Development stage
- Commercial
Overview
Four drugs have been commercialized, around 30 assets are undergoing clinical trials, and over 20 drug candidates are at the preclinical drug development stage
- Therapeutic areas
- Metabolic DisordersImmunologyOncologyNeurologyInfectious Diseases
- Modalities
- Monoclonal antibodiessmall molecule drugspolypeptide drugsantibody drug conjugates (ADCs)bi-specific or multi-specific antibodiesbispecific antibody drug conjugatesfusion proteinnucleic acid drugs
- Industry
- Biotech
Drug pipeline
55 assets54 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $2.8B
- Total revenue
- $364.9M
- Enterprise value
- $3.2B
Beyond the preview
Go deeper on Shanghai Junshi Biosciences Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Junshi Biosciences Co., Ltd..